FDA Approved: CABLIVI — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

FDA approved a supplemental application for CABLIVI (caplacizumab) filed by Genzyme Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• CABLIVI (CAPLACIZUMAB)

Snippet

SUPPL AP for CABLIVI (CAPLACIZUMAB)